Skip to main content
Premium Trial:

Request an Annual Quote

Gregory Schiffman, James Gibson, Kevin King, Robert Gottlieb

Gregory Schiffman has left his various senior executive positions at Affymetrix to take on the role of senior vice president and chief financial officer at Dendreon, a Seattle-based drug developer.
 
Affymetrix said last week that Schiffman resigned, effective immediately, from his posts as executive vice president, CFO, and treasurer, as well as other positions he holds at Affy subsidiaries.
 
The company said James Gibson will take over the role of principal accounting officer from his position as vice president of accounting and corporate controller. Gibson formerly served as director of finance and controller at Netflix.
 
Affy said it intends to start seeking candidates for the CFO and principal financial officer immediately.
 
Before working at Affymetrix, Schiffman held vice president positions at Applied Biosystems, Hewlett Packard, and IBM.
 
Affy also announced this week that Kevin King has been appointed president of the firm’s life sciences business and executive vice president. He previously served as president and CEO of Thomson Healthcare. Before that, King was vice president and general manager of global clinical systems for GE Healthcare.
 

 
Paris-based IntegraGen has appointed Robert Gottlieb to serve as CEO of the company’s US expansion effort, the firm said this week.
 
Gottlieb will take the helm at IntegraGen, Inc., which will be based in New York. He will continue to serve the parent company as vice president of global sales and marketing.
 
Gottlieb has worked at Abbott Laboratories, General Electric, Becton Dickinson, and Roche Diagnostics
 


 
Note to Readers: This is the last issue of BioCommerce Week to publish in 2006. The next issue of the newsletter will appear on Wednesday, Jan. 3.
The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.